Computational Biology Market Size & Growth Forecast 2027–2036, By Segments (Application, Service, End-use), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Computational Biology Market size was worth USD 6.89 billion in 2026 and is expected to grow at a 12.54% CAGR between 2027 and 2036, surpassing USD 22.45 billion by 2036. The industry revenue for 2027 is estimated at USD 7.62 billion.
Get more details on this report
Request Free Sample ReportComputational Biology Market Intelligence Snapshot
Regional Market Dynamics
- North America leads due to strong biotech and pharma clusters, advanced data infrastructure, skilled talent, and widespread use of computational tools across drug discovery and genomics research workflows.
- Asia Pacific growth at 14.67% CAGR is supported by expanding research capacity, rising use of data-driven methods, and broader adoption of computational platforms for sequencing, simulation, and target identification.
Segment Momentum
- Drug Discovery held a 28.99% share in 2026 because computational biology helps improve target identification, molecular modeling, and candidate screening, supporting more efficient and informed development decisions.
- Genomics is growing fastest as expanding sequencing activity generates complex datasets that require advanced computational tools for accurate analysis of gene expression, variation, and functional relationships.
Market Expansion Drivers
- Expanding AI-driven drug discovery platforms accelerating computational biology adoption across biopharma research.
- Rising genomics and personalized medicine research increasing demand for advanced bioinformatics analytics.
- Growing integration of cloud-based high-performance computing improving large-scale biological data processing efficiency.
Leading Market Participants
- Leading companies in the computational biology market include Illumina Inc. (United States), Thermo Fisher Scientific Inc. (United States), QIAGEN N.V. (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Schrödinger, Inc. (United States), Agilent Technologies, Inc. (United States), IBM Corporation (United States), Dassault Systèmes SE (France), DNAnexus, Inc. (United States), Genedata AG (Switzerland).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 6.89 billion
- 2027 Estimated Market Size: USD 7.62 billion.
- Projected Market Size: USD 22.45 billion by 2036
- Growth Forecast: 12.54% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Drug Discovery (Application) | Contract (Service) | Pharmaceutical Companies (End-use)
- Emerging Opportunity Segment: Genomics (Application) | Contract (Service) | Academic and Research Institutes (End-use)
Market Growth Drivers and Industry Trends
Expanding AI-driven drug discovery platforms accelerating computational biology adoption across biopharma research
The computational biology market is gaining momentum as AI-driven drug discovery platforms enable researchers to analyze complex biological datasets, identify potential therapeutic targets, and evaluate drug candidates with greater efficiency. Integration of machine learning and advanced computational models supports faster interpretation of molecular interactions and disease mechanisms, helping biopharmaceutical organizations streamline early-stage research and improve decision-making across discovery workflows. The growing use of AI-enabled analytical tools also increases the need for computational capabilities that can manage diverse biological information and support increasingly sophisticated research pipelines.
Rising genomics and personalized medicine research increasing demand for advanced bioinformatics analytics
The computational biology market will be propelled by expanding genomics and personalized medicine research, where large volumes of genomic and molecular information require advanced analytical capabilities for meaningful interpretation. Bioinformatics tools help researchers identify genetic variations, understand disease-associated pathways, and evaluate biological differences that can support more individualized therapeutic approaches. As research programs increasingly connect genomic information with clinical and molecular characteristics, demand is rising for analytical platforms capable of integrating and interpreting complex biological datasets across multiple research applications.
Growing integration of cloud-based high-performance computing improving large-scale biological data processing efficiency
Cloud-based high-performance computing is strengthening the computational biology market by providing scalable computing resources for processing increasingly complex biological datasets. Researchers can access substantial computational capacity without relying solely on fixed on-premises infrastructure, allowing analytical workloads to expand according to project requirements. Cloud environments also facilitate collaboration, data accessibility, and the execution of computationally intensive simulations and genomic analyses, while scalable processing architectures help research organizations manage growing data volumes more efficiently.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Expanding AI-driven drug discovery platforms accelerating computational biology adoption across biopharma research | 2.00% | Moderate | North America, Europe | High | Near Term |
| Rising genomics and personalized medicine research increasing demand for advanced bioinformatics analytics | 1.80% | High | North America, Asia Pacific | High | Mid Term |
| Growing integration of cloud-based high-performance computing improving large-scale biological data processing efficiency | 1.40% | Moderate | Asia Pacific, Europe | Emerging | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
In the computational biology market, North America held the largest share in 2026, supported by advanced biomedical research capabilities, strong adoption of computational tools, and well-established healthcare and biotechnology ecosystems. High demand for data-driven drug discovery, genomics, and personalized medicine is encouraging continued integration of computational methods across research and clinical workflows. Strong research infrastructure, access to specialized expertise, and sustained investment in life sciences further reinforce the region's market position.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is emerging as the fastest-growing regional market, driven by expanding biotechnology and pharmaceutical activities, increasing investments in healthcare infrastructure, and broader adoption of advanced computational technologies. Growing research capabilities and rising demand for genomics, drug discovery, and data-intensive biological analysis are creating favorable conditions for market expansion. The region's expanding scientific ecosystem and increasing focus on modernizing healthcare research are also supporting wider use of computational biology solutions.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Translational Research IntegrationGermany emphasizes computational biology platforms that connect academic research with pharmaceutical and clinical applications. German institutions focus on robust bioinformatics workflows, reproducible data analysis, and collaborative research environments that strengthen life sciences innovation.
France 🇫🇷
Clinical Data ModelingFrance strengthens computational biology through platforms that integrate clinical, genomic, and molecular datasets. French research organizations emphasize standardized analytical workflows and interdisciplinary collaboration to improve translational research and personalized healthcare initiatives.
Italy 🇮🇹
Academic Research CollaborationItaly adopts computational biology tools to enhance molecular research and collaborative life sciences projects. Italian universities and biotechnology organizations prioritize efficient data integration and bioinformatics capabilities that support biomedical discovery and applied research programs.
Japan 🇯🇵
Precision Genomics AnalyticsJapan applies computational biology to improve genomic interpretation and molecular research across healthcare and pharmaceutical sectors. Japanese organizations invest in advanced modeling tools and integrated biological datasets that support accurate disease characterization and therapeutic research.
South Korea 🇰🇷
Bioinformatics Platform ExpansionSouth Korea prioritizes computational biology solutions that support genomics, drug discovery, and biomedical research. South Korean institutions continue expanding cloud-enabled analytical capabilities and collaborative research infrastructure to improve the efficiency of biological data interpretation.
United States 🇺🇸
AI-Driven DiscoveryThe U.S. advances computational biology through integration of artificial intelligence, high-performance computing, and multi-omics analysis. U.S. research organizations and biotechnology companies prioritize scalable analytical platforms that accelerate target identification, biomarker discovery, and precision medicine development.
Segment Leadership and Growth Trends
Computational Biology Market Share (%), by Application, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportApplication Segment Analysis: Drug Discovery (Largest Segment) vs Genomics (Fastest-Growing Segment)
Drug discovery held the largest share of the application segment of the computational biology market, accounting for 28.99% in 2026. Its leading position reflects the increasing use of computational approaches to address the complexity of modern pharmaceutical research, including target identification, compound assessment, and candidate optimization. Computational biology can help researchers analyze large biological and molecular datasets more efficiently, supporting evidence-based decision-making throughout the discovery process. The growing pressure to improve research productivity and reduce inefficiencies in drug development is further strengthening demand for computational tools and analytical capabilities.
Genomics is anticipated to be the fastest-growing application as advances in sequencing and the expanding availability of genomic datasets increase the need for sophisticated computational analysis. The growing use of genomic information in disease research, precision medicine, and biological discovery is creating substantial opportunities for computational biology solutions. As researchers seek to interpret increasingly complex genetic information and translate genomic insights into actionable findings, demand for specialized computational capabilities is expected to accelerate.
Service Segment Analysis: Contract (Largest & Fastest-Growing Segment)
Contract services accounted for the largest share of the service segment of the computational biology market in 2026 and are also expected to represent the fastest-growing service category. The segment benefits from increasing demand for specialized computational expertise from pharmaceutical companies, biotechnology firms, and research organizations seeking to manage complex biological datasets and analytical workflows. Outsourcing enables organizations to access specialized capabilities without making extensive investments in internal infrastructure and technical teams. As computational requirements become more sophisticated and life sciences research becomes increasingly data intensive, greater reliance on contract-based expertise is supporting the segment's continued expansion.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Application | Drug Discovery, Disease Modeling, Genomics, Proteomics, Others | Drug Discovery | Genomics |
| Service | In-house, Contract | Contract | Contract |
| End-use | Academic and Research Institutes, Pharmaceutical Companies, Others | Pharmaceutical Companies | Academic and Research Institutes |
Competitive Landscape and Market Positioning
Major players in the computational biology market:
1. Illumina Inc. (United States)
2. Thermo Fisher Scientific Inc. (United States)
3. QIAGEN N.V. (Germany)
4. F. Hoffmann-La Roche Ltd (Switzerland)
5. Schrödinger Inc. (United States)
6. Agilent Technologies Inc. (United States)
7. IBM Corporation (United States)
8. Dassault Systèmes SE (France)
9. DNAnexus Inc. (United States)
10. Genedata AG (Switzerland)
The computational biology market is advancing through increased use of machine learning algorithms and simulation technologies that accelerate biological research and therapeutic discovery. Organizations are developing sophisticated modeling platforms capable of analyzing complex genomic and molecular interactions with greater accuracy. Continuous growth in precision medicine and biotechnology research is driving competitiveness within the computational biology market.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Illumina Inc. (United States) | |||||||
| Thermo Fisher Scientific Inc. (United States) | |||||||
| QIAGEN N.V. (Germany) | |||||||
| F. Hoffmann-La Roche Ltd (Switzerland) | |||||||
| Schrödinger Inc. (United States) | |||||||
| Agilent Technologies Inc. (United States) | |||||||
| IBM Corporation (United States) | |||||||
| Dassault Systèmes SE (France) | |||||||
| DNAnexus Inc. (United States) | |||||||
| Genedata AG (Switzerland). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Samsung Ventures; Cartography Biosciences | May-26 | Samsung Ventures made a strategic investment in Cartography Biosciences to support the company’s antibody-based oncology pipeline. The investment aims to enhance the firm's proprietary drug discovery platform, strengthening the application of AI-enabled and computational research approaches to identify novel therapeutic targets within oncology. |
| Amazon Web Services; OpenAI; Anthropic | May-26 | AWS, OpenAI, and Anthropic collaborated to launch specialized AI-driven workflows for the life sciences sector. Designed to accelerate drug discovery and scientific research, the infrastructure initiative reflects a broader shift among major technology firms to provide the computational foundation required for scaled AI-enabled biological research. |
| FairJourney Bio | Apr-26 | FairJourney Bio expanded its U.S. research infrastructure by opening a cryo-electron microscopy facility in San Diego. This move strengthens the company's structural biology and antibody discovery capabilities, providing critical technical resources necessary for high-resolution analysis in computational drug discovery workflows within a major biotechnology cluster. |
| Merck; Mayo Clinic | Mar-26 | Merck and Mayo Clinic launched an AI-driven precision medicine collaboration to accelerate drug discovery for autoimmune and neurological diseases. By integrating multimodal clinical, genomic, and longitudinal patient data, the partnership aims to improve target identification accuracy, demonstrating the clinical value of computational biology in advancing complex disease research. |
| Ten63 Therapeutics | Feb-26 | Ten63 Therapeutics raised $45 million in strategic funding to further develop its AI-driven drug discovery platform. This investment underscores the increasing commercial valuation of companies leveraging artificial intelligence to industrialize pharmaceutical research, particularly in the context of improving the speed and accuracy of target identification and lead optimization processes. |
| Excelsior | Dec-25 | Excelsior secured $95 million in funding, including a $70 million Series A round, to scale its discovery and production capabilities for small molecules. The investment is specifically directed toward expanding the company’s computationally enabled drug development infrastructure, reflecting the growing industrial focus on enhancing efficiency in early-stage pharmaceutical research. |
| ICL; Evogene; Lavie Bio | Apr-25 | ICL agreed to acquire the activities of Lavie Bio, a subsidiary of Evogene. This acquisition provides ICL with access to specialized computational biology-driven agricultural biotechnology capabilities, enhancing the company’s strategic position in the development of biologically based products through sophisticated data-driven discovery platforms. |
| Chan Zuckerberg Initiative; 10x Genomics; Ultima Genomics | Feb-25 | The Chan Zuckerberg Initiative partnered with 10x Genomics and Ultima Genomics to launch the Billion Cells Project. The collaboration aims to advance large-scale cellular and genomics research by leveraging expanded sequencing and computational analysis capabilities, fostering the development of infrastructure needed for high-throughput biological data interpretation. |
| Flagship Pioneering | Jul-24 | Flagship Pioneering raised $3.6 billion to fund the creation of approximately 25 startups focused on life sciences, artificial intelligence, and sustainability. This significant capital influx reinforces the broader investment momentum in computational biology-driven innovation and supports the ongoing development of advanced technology platforms within the sector. |
| Boehringer Ingelheim; Ochre Bio | Apr-24 | Boehringer Ingelheim entered a partnership with Ochre Bio, valued at over $1 billion, to advance liver disease treatments. The collaboration utilizes Ochre Bio’s computational and RNA-based discovery platform to identify therapeutic targets, highlighting the strategic integration of specialized computational biology capabilities by large pharmaceutical firms to enhance drug development pipelines. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Computational Biology Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Deployment Model | On-Premise, Cloud-Based, Hybrid |
| Computational Workflow Stage | Data Preparation & Integration, Modeling & Simulation, Analysis & Interpretation, Validation & Visualization |
| Data Type | Genomic Data, Proteomic Data, Transcriptomic Data, Structural & Molecular Data, Multi-Omics Data |
Computational Biology Market — Custom TOC
| Custom Chapter | Custom Details |
|---|---|
| AI-Driven Drug Discovery Adoption Outlook |
|
| Multi-Omics Integration Strategy Landscape |
|
| Biopharma Digital Capability Maturity Assessment |
|
Need a different cut of the data?
Request Custom ResearchWhat is the market valuation of computational biology?
What is the forecasted size of the computational biology industry?
How are AI-driven drug discovery platforms accelerating adoption in the computational biology market?
Why is cloud-based high-performance computing becoming increasingly important in the computational biology market?
What makes drug discovery the largest application segment in the computational biology market?
Why is genomics the fastest-growing application in the computational biology market?
Why is North America the leading region in the computational biology market?
What is driving rapid expansion of computational biology in Asia Pacific?
Which companies dominate the computational biology landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Reference |
|---|---|
| World Health Organization (WHO) | www.who.int |
| U.S. Food & Drug Administration (FDA) | www.fda.gov |
| European Medicines Agency (EMA) | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | www.cdc.gov |
| National Institutes of Health (NIH) | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | www.ncbi.nlm.nih.gov |
| PubMed | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | clinicaltrials.gov |
| International Organization for Standardization (ISO) | www.iso.org |
| ASTM International | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | mdic.org |
| Biotechnology Innovation Organization (BIO) | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | www.ifpma.org |
| U.S. Pharmacopeia (USP) | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | www.woah.org |
| American Hospital Association (AHA) | www.aha.org |
| OECD Health | www.oecd.org/health |
| World Bank Data | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization